Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Biohaven Ltd.NYSE: BHVN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $100.81M fell 45.3% year over year, behind the -32.9% change in trailing-twelve-month research & development. Sequentially, it fell 2.9% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -45.3% toward the trailing-twelve-month pace of -32.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 635.07M USD
- Year-over-year change
- -20.2%
- 4-year CAGR
- +36.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 635.07M | -20.2% |
| FY2024 | 2024-12-31 | 795.87M | +113.2% |
| FY2023 | 2023-12-31 | 373.28M | -14.6% |
| FY2022 | 2022-12-31 | 437.07M | +140.8% |
| FY2021 | 2021-12-31 | 181.49M | — |
Research & Development vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -32.9% is the lowest of 11, against a peer median of +21.7%.
- Over three fiscal years its annual growth of +13.3% compares with a peer median of +31.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $467.76M USD | -32.9% | +13.3% | — | |
| LTM Mar 2026 | $361.17M USD | -21.5% | -2.5% | 546.5% | |
| LTM Mar 2026 | $360.26M USD | +137.9% | +38.9% | — | |
| LTM Sep 2026 | $283.32M USD | +31.2% | +43.9% | 252960.7% | |
| LTM Jun 2026 | $261.87M USD | +51.3% | +45.5% | — | |
| LTM Mar 2026 | $259.11M USD | +17.2% | +34.4% | 67.2% | |
| LTM Sep 2026 | $236.54M USD | +35.6% | +95.7% | — | |
| LTM Sep 2026 | $186.28M USD | +1.9% | +20.1% | 274.5% | |
| LTM Sep 2026 | €132.22M EUR | +7.0% | +29.5% | — | |
| LTM Mar 2026 | $65.56M USD | +7.9% | +20.3% | — | |
| LTM Mar 2026 | $32.2M USD | +26.3% | +14.1% | 10.2% | |
| Peer median (excluding BHVN) | — | +21.7% | +31.9% | 274.5% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.14M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.14M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
| Selling, General & Admin | 37.41M | 130.86M | 62.77M | 89.24M | 106.17M |
| Operating Expenses | 218.9M | 567.93M | 436.05M | 885.11M | 741.24M |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| EBITDA | (211.04M) | (568.46M) | (402.64M) | (837.83M) | (727.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (218.9M) | (567.93M) | (436.05M) | (885.11M) | (745.38M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 17.73M | 21.33M | 14.59M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6.47M | (1.91M) | 26.5M | 39.42M | 8M |
| Income Before Tax | (212.43M) | (569.84M) | (409.55M) | (845.69M) | (737.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.37M | 438K | (1.38M) | 735K | 1.44M |
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| EPS (Diluted) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| Weighted Avg Shares | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
| Weighted Avg Shares (Diluted) | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.